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Abstract 27 
Background: Electrochemotherapy  combines electroporation in conjunction with 28 
chemotherapeutic agents and is used to treat tumours in many localisations, including 29 
cutaneous metastases. The symptoms associated with cutaneous malignant wounds can be 30 
distressing for patients and their management is a challenge in healthcare. 31 
Aim: The purpose of this systematic review was to investigate the effectiveness of 32 
electrochemotherapy in the context of palliative care. 33 
Design: All aspects of the systematic review were followed according to the Preferred 34 
Reporting Items for Systematic Reviews and Meta-Analyses statement.  35 
Data Sources: The following databases were searched for English-language reviews; 36 
Medline, Embase, CINAHL, British Nursing Index and the Cochrane Library. The search 37 
was conducted between the publication of Standard Operating Procedures in 2006 and the 38 
third week of October 2017. Studies involving oral cancers and studies with fewer than 10 39 
patients were excluded. The selected studies were assessed for risk of bias and sub-group data 40 
were synthesised in a random-effects meta-analysis.  41 
Results: From 425 studies, 29 studies were included involving 1,503 patients, the pooled 42 
results were 46.6% for complete response and 82.2% for objective response according to the 43 
Response Evaluation Criteria in Solid Tumours. The meta-analysis indicated that small 44 
tumours were over twice as likely (2.25) to have a complete response than large. 45 
Conclusions: Electrochemotherapy is an effective, repeatable and minimally invasive 46 
intervention within the palliative population that can reduce symptom burden. This review is 47 
an update of previous systematic reviews by Mali et al [1,2] and highlights the need for 48 
tailored treatment depending on each individual case. 49 
Keywords 50 
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1.0 Introduction 64 
1.1 Background 65 
Cutaneous metastases are a result of primary cancers infiltrating the skin. Although their 66 
appearance can be the first detected sign of malignancy [3], cutaneous metastases are 67 
generally a sign of advanced disease. The primary aim of managing these lesions is palliative. 68 
Their presence can have a devastating impact on quality of life due to factors such as loss of 69 
body image, malodour, pain, bleeding and the inability to contain exudate [4]. Managing 70 
these symptoms can prove a challenge for health care providers due to a lack of evidence-71 
based interventions for managing malodour as well as difficulties in managing exudate with 72 
dressings [5]. A number of skin directed therapies have been developed to try to mitigate the 73 
burden of cutaneous metastases with some varying levels of success [6]; in particular there is 74 
mounting evidence for the use of electrochemotherapy as a palliative treatment for both 75 
primary skin cancers and cutaneous metastases [5]. 76 
Electrochemotherapy consists of two stages; the first stage is the delivery of 77 
chemotherapeutic drugs, this is then followed by the application of electric pulses directly 78 
into the tumour approximately eight minutes later. This causes a temporary increase in the 79 
permeability of the plasma membrane of the tumour cells resulting in a rise in localised drug 80 
uptake [7]. Therefore, the aim of electroporation is to increase the absorption of 81 
chemotherapeutic drugs into cutaneous and subcutaneous cancerous cells, thereby increasing 82 
their concentration and thus their effectiveness.     83 
A large study led by Marty et al. [8] led to the publication of Standard Operating Procedures 84 
and this defined the benchmark for best practice in this field and led to standardised practice 85 
of electrochemotherapy internationally.  Further clinical trials with large sample sizes have 86 
established electrochemotherapy as an effective and safe treatment [9]. In 2018, the Standard 87 
Operating Procedures were updated to reflect the experiences obtained with its use in 88 
practice. The key changes noted in this update include robust recommendations regarding 89 
which treatment strategy to employ according to specific patient characteristics. For instance, 90 
in patients with less than seven tumours, smaller than 3cm in size local anaesthesia and local 91 
drug injection is suggested, whereas, in patients with more than 7 tumours, larger than 3cm in 92 
size general anaesthesia and intravenous drug administration is suggested. In addition, advice 93 
is given regarding the type of electrode to use according to the characteristics of individual 94 
tumours. The update also gives a comprehensive criteria that should be used to determine 95 
whether a patient is suitable for electrochemotherapy as well as standards for documentation 96 
and imaging, patient follow-ups and how to deal with reoccurrence [10].   97 
Advantages of electrochemotherapy, such as its ability to eliminate or reduce tumours to a 98 
manageable size, in turn minimises distressing symptoms and avoids unnecessary surgery to 99 
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excise tumours [11]. These make it a highly significant intervention in the context of 100 
palliative care.  101 
Two systematic reviews published in 2013 by Mali et al. [1-2] led to NICE (National Institute 102 
of Clinical Excellence) recognised electrochemotherapy as a palliative treatment for treating 103 
metastases in the skin from tumours of non-skin origin and melanoma [12]. A drawback of 104 
these reviews is that they included studies conducted before the publication of the Standard 105 
Operating Procedures in 2006 [8]. It is therefore worthwhile to review the evidence again 106 
since their publication, to exclusively evaluate the studies published since its implementation 107 
and minimise the heterogeneity which was present in the previous review.  108 
 109 
 110 
1.2 Objective  111 
The primary objective of this systematic review was to examine the available evidence for the 112 
use of electrochemotherapy to draw conclusions about its effectiveness with the primary 113 
objective of tumour response, and to make recommendations for its usage in the context of 114 
palliative care. A secondary objective was to examine the relationship between tumour size 115 
and response to treatment using a meta-analysis, again to update the previous reviews with 116 
the most recent evidence. 117 
 118 
2.0 Methods 119 
2.1 Protocol and registration 120 
This systematic review and meta-analysis were conducted at King’s College London (2018). 121 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 122 
(PRISMA) was used as a guide to the reporting of all aspects of this systematic review [13]. 123 
 124 
2.2 Eligibility criteria 125 
Studies were eligible if they had been published after the publication of the Standard 126 
Operating Procedures in 2006 and reported data on tumour response after the delivery of 127 
electrochemotherapy with at least a four-week follow up. Case reports or studies involving 128 
fewer than 10 patients were unnecessary to include as there was an adequate number of 129 
studies with large sample sizes. Studies involving primarily oral cavity cancers were 130 
excluded as this was deemed a heterogeneous population. Studies were eligible for meta-131 
analysis if they had separate data for tumour response according to size and were of an 132 
acceptable homogeneity.  133 
The primary outcome was tumour response according to the RECIST (Response Evaluation 134 
Criteria In Solid Tumours) method [14]. These criteria define a complete response (CR) as 135 
the disappearance of all target lesions, partial response (PR) as a decrease of at least 30% in 136 
the sum of the longest diameters of all target lesions and objective response (OR) as sum of 137 
CR and PR. 138 
 139 
2.3 Information Sources 140 
The following databases were searched; Medline, Embase, CINAHL, British Nursing Index 141 
and the Cochrane Library. The search was performed during the third week of October 2017. 142 
Language restriction to English was applied as translation resources were unavailable for this 143 
review. 144 
  145 
2.4 Search 146 
 147 
To inform the search strategy the PICO format (population, intervention, comparison and 148 
outcome), was used to identify the key concepts in the review question. The Comparison 149 
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facet was omitted from the PICO table because only observational studies including 150 
prospective, retrospective studies and case series were identified in the preliminary literature 151 
search. The reason for the lack of randomised trials is likely due to the ethical concerns 152 
around conducting a trial in a palliative population and the lack of clinical equipoise relating 153 
to the intervention [15] (see supplementary material 1 for full search strategy).  154 
 155 
 156 
2.4.1 Study selection and data extraction 157 
The study selection process was performed by one independent researcher. After removal of 158 
duplicates the title and abstracts of all remaining papers were screened against the 159 
inclusion/exclusion criteria and those deemed ineligible were removed. The full-text of the 160 
remaining papers was studied and the irrelevant studies were excluded with reasons (figure 161 
1).  162 
The data were extracted from the selected studies by one researcher and displayed in 163 
evidence tables (tables 1 and 2). These studies were then screened again against the eligibility 164 
criteria for meta-analysis and the data on tumour size and response extracted (table 3). 165 
 166 
2.4.2 Data items 167 
According to the PICO format [15]; the Population was cutaneous metastases, the 168 
Intervention was electrochemotherapy and Primary Outcome was clinical response, the 169 
Comparison facet was not included due to the lack of a comparator. 170 
The information extracted from each study was as follows; study type, included number of 171 
evaluable patients, tumour response, response evaluation time, drug route, type of tumour and 172 
response evaluation method. These headings were chosen due to their similarity to the 173 
headings used in the previous systematic review [1], so comparisons could be made. A 174 
further evidence table (table 2) extracted the available data relating to further cycles of 175 
electrochemotherapy and secondary outcomes such as survival analysis, as this information 176 
would provide context to the use of electrochemotherapy in the field of palliative care. 177 
The headings included in the evidence table for meta-analysis (table 3) were; total number of 178 
small tumours and number of those achieving complete response, number of large tumours 179 
and number achieving complete response. The criteria for small and large tumour sizes were 180 
set by the individual studies and therefore studies were only included if the definition of the 181 
groups were homogeneous between studies. 182 
    183 
2.5 Risk of bias in individual studies 184 
In the case of this review the included studies were observational, prospective or 185 
retrospective case series designs. Although randomised controlled trials (RCTs) are 186 
considered the most rigorous method for determining the effectiveness of an intervention they 187 
were not present in the literature around electrochemotherapy during scoping searches. This 188 
is likely due to a lack of clinical equipoise, as electrochemotherapy has already been 189 
established as an effective palliative treatment; [1,2] therefore it would be deemed unethical 190 
to enter patients into an RCT where one intervention is believed superior to another [16]. In 191 
addition interventions for managing key symptoms (exudate and malodour) are currently 192 
lacking [5].  193 
A tool developed to assess the methodology of observational case series studies was 194 
identified, which contains an 18-criteria checklist (see supplementary material 2 for checklist) 195 
[17]. This checklist has been validated in a systematic review of quality assessment tools [18] 196 
and was deemed the most appropriate tool to assess the quality of papers in this systematic 197 
review. 198 
 199 
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2.6 Summary Measures  200 
The overall effectiveness of electrochemotherapy was determined by pooling the primary 201 
outcome data of all individual studies to calculate an overall weighted per patient Complete 202 
Response % (CR) and Objective Response % (OR).  203 
 204 
2.7 Synthesis of results 205 
A meta-analysis was used to compare sub-groups to evaluate the differences in anti-tumour 206 
effectiveness of electrochemotherapy on tumours of different sizes. For the purposes of sub 207 
group analysis, the studies with separate data for ‘small’ and ‘large’ tumours were used with 208 
‘small’ defined as ≤3cm and ‘large’ as >3cm. The relative risk (or risk ratio) was used as the 209 
measure of the size of the effect. 210 
The random- effects model was used in the meta-analysis as electrochemotherapy is a 211 
potential treatment for a wide range of tumour histologies and therefore applies to a wide 212 
patient population [19]. The I2 statistic was used to measure the variability between studies 213 
and to interpret the impact of heterogeneity on the MA; with I2<25% showing homogeneity 214 
and I2>75% showing considerable heterogeneity [20]. The calculations used were written in 215 
the Meta package which runs in the R programme according to the user manuals and forest 216 
plots were generated (figure 2) [21].  217 
 218 
2.8 Risk of bias across studies 219 
The concept of publication bias is an underlying issue within healthcare research and should 220 
be considered as a risk in systematic reviews and meta-analysis [22]. Investigating 221 
publication bias in a meta-analysis is usually done by performing a funnel plot, however, due 222 
to limited access to meta-analysis software this was not undertaken in this review. 223 
Selective reporting of bias should be investigated by comparing the methodology of a paper 224 
with the reported outcomes to make sure there is consistency between the outcomes listed in 225 
the methods section and the results reported in the findings section [23]. Any obvious 226 
reporting failures in the studies included became obvious in the data extraction process and 227 
these studies scored less in the quality appraisal tool.   228 
 229 
3.0 Results 230 
3.1 Study Selection 231 
The database search generated 425 studies after removal of duplicates. The title and abstracts 232 
of these studies were screened against the inclusion/exclusion criteria and 390 studies 233 
excluded as irrelevant. The 41 remaining studies were selected for further evaluation, the full 234 
text was obtained, read and screened against the eligibility criteria and 29 deemed eligible to 235 
be part of the review. Studies that did not meet the eligibility criteria were excluded and the 236 
reason for exclusion is detailed in the PRISMA flow chart (figure 1). The included studies 237 
were screened again against the inclusion criteria for the meta-analysis and five selected as 238 
satisfying the criteria. 239 
 240 
 241 
3.2 Study Characteristics 242 
All studies were observational and there was a combination of both prospective and 243 
retrospective approaches. The majority of studies used the Response Evaluation Criteria in 244 
Solid Tumours method [14] to measure tumour response and the follow-up period to tumour 245 
evaluation ranged between 30 days and three months.  246 
As expected, there was a wide range of tumour types across the studies; the most common 247 
being Melanoma, Basal Cell Carcinoma (BCC) and metastatic Breast Cancer. All studies 248 
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with the exception of two [24, 25] reported the maximum number of electrochemotherapy 249 
cycles performed and the number of patients that received more than one course of 250 
electrochemotherapy. Where reported, the range of number of electrochemotherapy cycles 251 
was between two and six. Some studies reported patient outcomes such as pain and quality of 252 
life.  253 
There was a lack of information across all the studies on the way survival analysis was 254 
calculated, perhaps due to the word restriction on publications. In addition, there was 255 
inconsistency between papers on the way they reported the survival analysis. Some reported 256 
progression free survival for the whole cohort of patients whereas others only calculated it for 257 
the patients with complete response.  258 
Serious adverse events were minimal. The only serious adverse event that was considered 259 
related to the intervention was reported by Bertino et al. [9] where one patient with a large 260 
ulcerated tumour died from septic shock on the second day post-electrochemotherapy. The 261 
most common reported systemic reactions were mild, post-procedural nausea and dizziness 262 
being the most common. Pain was the second most reported adverse reaction, but this was 263 
reported as transient and although some reports of extreme pain were made immediately after 264 
the therapy, this settled to manageable pain within around 48 hours.  The incidence and 265 
description of treatment toxicity was graded according to the Common Terminology Criteria 266 
for Adverse Events (CTCAE) in the majority of studies. The most frequently reported 267 
complications were skin-related such as ulceration, erythema, and other inflammatory 268 
reactions, the most severe of these were graded 4 according to the CTCAE. However, across 269 
the studies all of these were transient and did not result in permanent damage. A number of 270 
studies asked patients whether they would agree to further electrochemotherapy treatment 271 
after the initial session and the percentage of patients that answered favourably was high. For 272 
instance, in Cabula et al. [24] 97% of 96 patients answered that they would agree to receive 273 
the treatment and in Matthiessen et al. [26] 90% of 51 patients were in favour of re-treatment. 274 
 275 
  276 
3.3 Quality Appraisal and risk of bias across studies  277 
The 18-criteria checklist was used to assess the quality of included studies [17]. A study 278 
scored a point when it fulfilled a criterion with the scores displayed in table 4. Overall, 17 279 
studies of the 21 assessed received a score of 14 or more and were deemed of satisfactory 280 
quality. 281 
The researchers in this field have tried to overcome the weaknesses in their methodology by 282 
reporting the baseline characteristics of their patient populations in order to be transparent to 283 
the reader and to mitigate selection bias. This means judgements can be made about the 284 
suitability of the included patients and whether the conclusions made at the end of the study 285 
were robust. Only two of the included studies failed to report the baseline characteristics of 286 
participants, [27, 28] and these papers were awarded low scores in the quality appraisal tool. 287 
Another aspect that increased rigour was the use of standardised outcome measurement tools. 288 
In this case the majority of the papers (20 out of 29) used the Response Evaluation Criteria In 289 
Solid Tumours method [14] to measure tumour response, with the remaining using the WHO 290 
criteria [29] or stating their own measures, which in both cases were adequately similar to the 291 
Response Evaluation Criteria In Solid Tumours model. However, there was inconsistency 292 
across the studies in the timing of the tumour evaluation with a range of 30 days – three 293 
months, with three studies not reporting the time period to tumour evaluation and these 294 
papers were marked down in the quality appraisal [30-32].  295 
The majority of studies in this review were prospective (n=21) with the remaining being 296 
retrospective analyses (n=8).  It is generally the view that retrospective design is weaker in 297 
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the hierarchy of evidence than prospective design [33]. However, in this review there was not 298 
a significant difference in quality between the retrospective and prospective studies. This 299 
demonstrates that the labelling of studies does not automatically classify whether they are 300 
superior or inferior but a more thorough examination of what has been reported in the papers 301 
is required [34]. 302 
 303 
  304 
3.4 Synthesis of results 305 
The pooled data across all the studies which evaluated the tumour response per patient was 306 
46.6% for complete response and 82.2% for objective response, the total number of patients 307 
being 1194. For six studies, the data were presented as ‘per tumour’ evaluation of response 308 
and the pooled result for these data was 53.6% for CR and 71.5% for OR, the total number of 309 
tumours was 599. 310 
 311 
3.5 Meta-Analysis 312 
The five studies found eligible for meta-analysis were among the highest scoring in the 313 
quality appraisal exercise with scores ranging from 15 – 17 out of 20. Table 3 shows the data 314 
extracted. 315 
The total number of ‘small’ tumours included in the analysis was 602 and the pooled CR for 316 
this group was 67.4%. In contrast, the total number of ‘large’ tumours was 185 with a pooled 317 
complete response of 33.0%. The forest plot (figure 2) takes the ‘large’ tumour group as the 318 
control group and the ‘small’ tumour group as the experimental group. The overall relative 319 
risk in the random effects model is 2.25 95% confidence interval [1.58-3.2]. This means that 320 
‘small’ tumours ≤3cm are over twice as likely (2.25) to have a complete response than ‘large’ 321 
tumours >3cm. The test for overall effect generated a p value of <0.01 which is statistically 322 
significant, as the level of significance was set as p<0.05.  323 
The I2 statistic was 52% indicating there is moderate heterogeneity.  The p value associated 324 
with the Chi-squared test for heterogeneity is 0.08 which is statistically significant, 325 
demonstrating that the random-effects model was appropriate to use in this instance. It is 326 
important to note that the I2 in this meta-analysis will not be very precise due to the very 327 
small number of studies and the inability to detect the between study variance [19].  328 
 329 
 330 
3.6 Risk of bias across studies 331 
During the quality assessment process, the study by Di Monta et al. [37] only reported 332 
complete response data in the results section despite describing the Response Evaluation 333 
Criteria in Solid Tumours criteria and defining partial response as a primary outcome in the 334 
methods section. This meant that the objective response (the complete response + partial 335 
response) could not be calculated for this study and therefore there was an absent score for 336 
OR% when the data across all studies were pooled.  337 
When selecting studies suitable for meta-analysis it was noticed that in the study by Curatola 338 
et al. [38] the percentage response data for small tumours and large tumours was reported, 339 
but, the number of tumours in the two sub-groups was not, which meant there was not enough 340 
raw data to be included. Similarly, the results for small versus large tumours in the study by 341 
Campana et al.[39] could not be included in the meta-analysis because only the statistical test 342 
results such as odds ratio and p-value were reported and not the raw data. It was not possible 343 
to contact the authors of these studies for the raw data due to time constraints.  344 
 345 
4.0 Discussion 346 
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4.1 Summary of Evidence 347 
All the studies identified in the review reported results in favour of electrochemotherapy for 348 
the primary outcome of tumour response; it was well tolerated by patients and there were few 349 
reported serious adverse reactions.  350 
The findings of this review are consistent with the previous systematic reviews on 351 
electrochemotherapy. It is noteworthy that in this review all the studies used bleomycin 352 
exclusively as the chemotherapeutic agent except for Campana et al. [30, 40] where cisplatin 353 
was used for a small proportion of study participants. In contrast, the previous review 354 
included six studies that used cisplatin exclusively. The reason for this move towards 355 
bleomycin as the drug of choice is likely due to further evidence generated since the 356 
publication of the previous studies which showed that the uptake of bleomycin is potentiated 357 
more effectively by electroporation pulses than the uptake of cisplatin and therefore future 358 
studies began to use the bleomycin drug exclusively [41]. 359 
The meta-analysis used to perform sub-group analysis comparing the treatment response 360 
found there was a statistically significant increase of 125% in the probability of complete 361 
response for tumours ≤ 3cm compared to tumours >3cm. These findings are consistent with 362 
the previous meta-analysis [1, 2]. The reasons for this significant difference in the 363 
effectiveness of electrochemotherapy depending on tumour size has been considered in the 364 
literature [26, 42, 43] and it is believed to be multi-factorial. Firstly, in large tumours there 365 
may be insufficient exposure of the tumour to the chemotherapy drug due to inadequate blood 366 
flow across the tumour as it is harder for the drug to penetrate the centre of a larger tumour 367 
[44], therefore the drug is not adequately distributed to provide the optimum 368 
chemotherapeutic effect. Secondly, there may be insufficient coverage of the larger tumours 369 
by the electric fields simply due to the difficulty in applying the electrodes to the larger 370 
tumours, which will generally be of a less uniform size compared to the smaller tumours.  371 
Another potential explanation for why small tumours respond better to electrochemotherapy 372 
is because they have faster healing times and the fact that large tumours may be more 373 
aggressive [36]. These potential shortfalls associated with treating larger tumours could be 374 
managed with individualised treatment planning to ensure the most effective choices of type 375 
of electrode and drug administration methods are assessed in all patients prior to instigation 376 
of the therapy. This review highlights the fact that electrochemotherapy is not a one-off 377 
treatment and can be repeated.   378 
There were a number of further sub-group analyses across the studies in addition to tumour 379 
size. These include; in the study by Rotunno et al. [45] where response for 380 
electrochemotherapy performed under general versus local anaesthesia was compared and 381 
found a significant increase in CR% for patients who underwent general anaesthesia. In 382 
addition, in the study by Bertino et al. [9] the response of tumours that were treatment-naïve 383 
was compared with tumours that had been previously treated with surgical-excision or 384 
irradiation. The authors found the treatment-naïve tumours responded significantly better 385 
than the previously treated tumours. These additional analyses further enrich the breadth of 386 
knowledge about the usefulness of electrochemotherapy and provide valuable information for 387 
the review question and implications for future research. 388 
 389 
4.2 Limitations 390 
Overall, the methodological quality of the included studies was acceptable. Baseline 391 
characteristics were reported in the majority of studies, the outcome measure was fairly 392 
consistent across the included studies. However, there was inconsistency across the studies in 393 
the timing of the tumour evaluation with a range of 30 days – three months, with three studies 394 
not reporting the time period to tumour evaluation [30-32]. This makes it very difficult to 395 
form any robust conclusions about their data. It is difficult to judge how much of an effect the 396 
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difference in time to evaluation had on the reliability of the results, but it is noteworthy that 397 
the Standard Operating Procedures recommended a period of four weeks before treatment 398 
efficacy of electrochemotherapy can be determined.  399 
The survival analysis was poorly reported and inconsistent across the studies which is 400 
unfortunate as these data are of great interest to clinicians particularly when deciding whether 401 
a treatment is worthwhile in the context of palliative care. The data extracted from the studies 402 
do give an indication of the medium length of follow-up in each individual study and 403 
percentage of patients whose disease was kept at bay. It is therefore useful information to 404 
display regardless of the fact that it is not possible to obtain an overall pooled average 405 
survival statistic. 406 
Another limitation of the included studies was the use of co-interventions. These are 407 
significant as they illustrate that there are fundamental differences in the experience of a 408 
portion of patients within the studies due to adjunct treatments which may affect the tumour 409 
response data. It may also be this was more widespread than can be identified in the full-text 410 
articles if some articles did not publish the additional interventions the patients underwent in 411 
their studies. However, it can be argued that due to the disease severity of the patients in 412 
these studies it would be considered unethical to deny them the opportunity to be exposed to 413 
other tumour-targeting therapies that may assist them to alleviate the burden of living with 414 
metastatic cutaneous tumours.     415 
Overall, this systematic review includes a representative sample of the available literature on 416 
this topic area for meaningful conclusions to be made. The study selection, data extraction 417 
and study appraisal aspects of this review were carried out appropriately however, they would 418 
have been much more robust if there had been a second reviewer. Due to the availability of 419 
studies with large sample sizes, studies with less than ten participants were excluded to 420 
purposely limit the number of studies for analysis. However, the fact this occurred meant 421 
some very pertinent articles were removed that would have increased the knowledge to 422 
answer the review question [46-48]. 423 
 424 
The methods of statistical analysis were appropriate and valid in this review and an academic 425 
statistician was consulted for guidance on conducting the meta-analysis. Unfortunately, there 426 
was poor precision due to the fact there were only five studies eligible for the analysis, and it 427 
may therefore be misleading to draw firm conclusions from the summary effect.  428 
 429 
4.4 Conclusions 430 
This aim of this systematic review was to consolidate the recent literature on the effectiveness 431 
of electrochemotherapy for cutaneous metastases and update the previous systematic reviews 432 
[1, 2]. It was evident during the review process that the period of four weeks recommended 433 
by the Standard Operating Procedures as the time to measure tumour response to 434 
electrochemotherapy may not be long enough for large tumours to respond. In the study by 435 
Matthiessen et al. [26] the patients all had large tumours from breast cancer and used an eight 436 
week follow up instead of the four weeks to allow for this. Another factor noted in this 437 
review is that larger tumours may benefit from using different plates and electrodes. 438 
Additionally, a higher concentration of drug in large tumours could be achieved by 439 
combining both intratumoural and systematic administration of chemotherapy. This review 440 
used meta-analysis to show that small tumours have a greater tumour response compared to 441 
large tumours, further meta-analyses comparing other sub-groups would be useful in future 442 
reviews such as whether previous irradiation and number of tumours per patient influences 443 
the effectiveness of electrochemotherapy. Matching the treatment modality and schedule to 444 
patient specific factors such as those identified above is crucial to ensure the most effective 445 
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coverage of the tumour by the electric field which means treatment needs to become more 446 
tailored to the individual. 447 
Another implication for future treatment is that many of the studies reported some 448 
participants were able to obtain and/or maintain tumour response by undergoing repeated 449 
sessions of electrochemotherapy. Unfortunately, there was a lack of data providing the 450 
tumour responses to the additional cycles of electrochemotherapy. Further research should 451 
aim to explore this to set standards for the frequency of electrochemotherapy sessions to 452 
provide the highest benefit and lowest possible harm to patients. This could be done by better 453 
reporting of the number of cycles and results of the retreatments. Another issue this review 454 
has exposed is the lack of consistency in reporting of survival statistics as well as secondary 455 
outcomes such as QOL, pain and toxicity. Future research should address these outcomes as 456 
they inform health resource use and patient preference especially in palliative care. 457 
This systematic review shows electrochemotherapy is an effective palliative treatment with 458 
minimal adverse reactions. Moreover, it should be considered early in the development of 459 
cutaneous metastases as the smaller the tumour the more effective the treatment. Larger 460 
tumours will need to have tailored approaches to maximise the effectiveness of the ECT 461 
treatment, such as using different plates and electrodes.  462 
The evidence included in this review is based on the studies conducted following publication 463 
of the standard operating procedures in 2006 [8], it is noted that there has been an updated 464 
version of these standard operating procedures published in 2018 [10]. This update reflects 465 
the considerable experience gained in the use of the treatment in a wide range of tumour 466 
histologies. Future studies going forward, which use the updated standards may generate 467 
further clinically specific evidence to guide clinicians. The knowledge generated by this 468 
review provides evidence generated from clinical studies, which followed the 2006  Standard 469 
Operating Procedures [8, 10] and inform clinical practice guidelines such as the NICE 470 
guidelines [12] to ensure they are brought up-to-date with current evidence.  471 
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